Seal Rock Therapeutics says its novel oral therapy program SRT-055, which aims to treat Parkinson’s disease and other neurological disorders, showed powerful neuroprotective effects in preclinical experiments. The company now plans to advance the program’s development for Parkinson’s — and then will move toward the treatment of…
News
IRLAB Therapeutics has selected a dopamine receptor agonist candidate called IRL1117 to advance as a Parkinson’s disease treatment, potentially as a longer-lasting alternative to levodopa with lesser side effects. IRL1117 is designed to be a once-daily oral therapy for the hallmark symptoms of Parkinson’s — tremors, rigidity, and slowness of…
Subthalamic deep brain stimulation (DBS) significantly eases motor and non-motor symptoms in people with early-onset Parkinson’s disease, a new study suggests. In fact, data showed that individuals with this early-onset form of the neurodegenerative disorder saw more than a 50% improvement, or lessening of motor symptoms, on one…
Levels of nerve cell pentraxin proteins found in the cerebrospinal fluid (CSF) surrounding the brain and spinal cord are associated with motor and cognitive decline in people with Parkinson’s disease and related conditions, a study suggests. As such, these nerve pentraxins may serve as predictive biomarkers for both…
Increasing doses of KM-819, a potential therapy being developed by Fascinate Therapeutics for Parkinson’s disease, showed a favorable safety profile in healthy older adults, according to data from the now-completed Part 1a of a Phase 2 trial. The placebo-controlled trial (NCT05670782), which was launched last year, is…
The world-first Phase 3 clinical trial testing the ability of ambroxol, a medicine used for decades to treat lung conditions, to slow Parkinson’s disease progression is expected to start in the next few months. Called ASPro-PD, the end-stage trial is supported by results from the previous Phase 2…
A clinical trial testing the impact of low doses of psilocybin, a naturally occurring psychedelic compound, on inflammatory activity in people with Parkinson’s disease is on track to be completed by the end of February. Sponsored by Silo Pharma and conducted at the Clinical & Translational Science Institute (CTSI)…
The Parkinson’s Foundation is expanding its Global Care Network with a membership program — called Community Partners in Parkinson’s Care — to better equip senior living communities and home care agencies to care for people with Parkinson’s disease. The foundation’s Global Care Network is made up of…
Centogene is expanding enrollment in the Rockstock International Parkinson’s Disease (ROPAD) gene study — the world’s largest research effort to characterize the genetic profile of people with Parkinson’s disease. The global study now will recruit participants at 48 sites across 10 countries: the U.S., Argentina, Brazil, the…
Neurocrine Biosciences has acquired rights to Voyager Therapeutics’ experimental gene therapy program for Parkinson’s disease associated with mutations in the GBA1 gene and for other GBA1-mediated diseases. The collaboration agreement also includes three gene therapy programs for rare diseases of the central nervous system (CNS;…
Recent Posts
- Blocking 2 proteins could slow Parkinson’s progression: Study
- How to minimize stress while traveling with Parkinson’s disease
- New PET tracer helps scientists ‘see’ Parkinson’s toxic protein clumps
- Tech duo to advance brain-penetrating drugs for CNS disorders
- New trial offers extended buntanetap access for people with Parkinson’s